# Erik Jakobsen

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/erik-jakobsen/

## Facts

| Field | Value |
| --- | --- |
| Citations | 18,364 |
| Field | Lung Cancer Diagnosis and Treatment |
| h-index | 47 |
| i10-index | 116 |
| Last Known Institution | Odense University Hospital |
| OpenAlex ID | https://openalex.org/A5068369453 |
| ORCID iD | https://orcid.org/0000-0002-0052-7705 |
| Works | 263 |

## Researcher papers

- [Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer](https://scholariq.org/papers/ribociclib-as-first-line-therapy-for-hr-positive-advanced-breast-cancer/)
- [Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer](https://scholariq.org/papers/tucatinib-trastuzumab-and-capecitabine-for-her2-positive-metastatic-breast/)
- [Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/neratinib-after-trastuzumab-based-adjuvant-therapy-in-her2-positive-breast/)

## Researcher topics

- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Global Cancer Incidence and Screening](https://scholariq.org/topics/global-cancer-incidence-and-screening/)

## Researcher university

- [Odense University Hospital](https://scholariq.org/institutions/odense-university-hospital/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.